At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 73 enrolled
Drug / intervention
Belumosudil +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025)
In Brief
A Phase 1 clinical trial evaluating Belumosudil, Itraconazole, and 3 other interventions for Drug-drug Interaction and 2 related conditions. Completed, enrolled 73 participants across 1 site.
Detailed Summary
This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug-drug Interaction, Autoimmune Diseases, Fibrotic Disease
CountriesUnited Kingdom
CollaboratorsQuotient Sciences
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedMay 2018
Primary CompletionFeb 2019
TodayJul 2026
First PostedMay 21, 2018
Enrollment StartApr 9, 2018
Primary CompletionFeb 8, 2019
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.1 years ago
Interventions
Belumosudildrug
Development candidate
Itraconazoledrug
Perpetrator drug
Rabeprazoledrug
Perpetrator drug
Rifampicindrug
Perpetrator drug
Omeprazoledrug
Perpetrator drug